The effects of fluoxetine (FLU) and its active metabolite, norfluoxetine (NFLU), on the polysomnogram (PSG) of nine depressed outpatients (eight with major depression; one with bipolar II, depressed phase disorder) were investigated by contrasting PSG values prior to treatment and during administration of FLU. The PSG changes were correlated with daily dose, cumulative dosage, single serum concentrations, and the total area under the serum concentration curve (AUC) of both FLU and NFLU.
Fluoxetine clearly increased both stage 1 sleep time and rapid-eye-movement (REM) latency and decreased both percent REM and REM density. With a few exceptions, the cumulative dosage of FLU and the AUC of FLU and NFLU were better predictors of the changes in awake and movement time in the PSG than single-sample concentrations of FLU and NFLU taken at the time of PSG assessment. fNeuropsychopharmacology 10: 85-91, 1994J sleep that is reflected in increases in sleep latency and percentage of non-REM stage 1 sleep and decreases in total sleep time, sleep efficiency, and percentage of non REM stages 3 and 4 sleep (Nicholson and Pascoe 1986; Pastel and Fernstrom 1987; Kerkhofs et al. 1990; Keck et al. 1991; Keck and McElroy 1992) . The duration of REM sleep and REM latency, as well as REM density, may also be affected by FLU (Nicholson and Pascoe 1988; von Bardeleben et al. 1989; Nicholson et al. 1989; Bakalian and Fernstrom 1990; Hanzel et al. 1991; Saletu et al. 1991) . These effects likely depend upon both the dose and duration of FLU treatment.
Changes in polysomnogram (PSG) measures as sociated with chronic FLU treatment in depressed sub jects have been incompletely studied (Schenck et al. 1992) . Relationships among PSG measures and serum concentrations of FLU and its active metabolite norflu oxetine (NFLU) have not been previously reported in depressed patients. This pilot study evaluated the effect of FLU and NFLU on PSG measures in a group of medication-responsive depressed outpatients.
METHODS

Subjects
Subjects were selected from a pool of self-referred pa tients (n = 5) and symptomatically depressed volun teers (n = 4) who were recruited by local advertise ments. Following a screening visit, potential subjects had full clinical evaluations, which included adminis tration of the Structured Clinical Interview for DSM III-R (Spitzer et al. 1986 ). Evidence of general medical, sleep, or neurologic disorders was exclusionary. Only nonsteroidal, antiinflammatory agents were permitted during the 2-week period preceding PSG evaluations. Depressive symptom severity was measured by the 17-item Hamilton Rating Scale for Depression (HDRS-D) (Hamilton 1960 ) and the 30-item Inventory of Depres sive Symptomatology, Clinician-Related Version (IDS-C) (Rush et al. 1986) .
At the time of the study, diagnosis for all patients was nonseasonal, nonpsychotic, major depression, sin gle or recurrent type, with moderate to severe symp toms, as evidenced by a 17-item HDRS-D score greater than 16. Patients with a history of any other psychiatric disorder, including psychoactive substance abuse, were dropped from consideration for the study. No subject had ever received prior treatment with FLU. Table 1 describes the sample. 
Procedures
Each subject's requirement for and adequacy of noc turnal sleep had been identifIed and frrrnl y established in advance of both PSG assessments. During the week preceding these recordings, patients maintained as-day sleep diary to document regularity of bed and rise times, nightly net sleep, and sleep quality. Napping was pro scribed. Each patient retired and rose at individualized clock times. These were established following consul tation with the patient and examination of the infor mation recorded in the patient's sleep diary.
Prior to treatment with FLU, baseline PSG assess ments were conducted during 2 consecutive nights in the Department of Psychiatry Sleep Study Unit of the University of Texas Southwestern Medical Center. All patients were drug free for at least 2 weeks prior to the initial night of PSG recording.
The electroencephalogram (EEG) was recorded from central sites referenced to contralateral ear lobes (C3-A2, C4-A1) on a polygraph (GRASS model 78; Quincy, MA) equipped with 7P-511 AC amplifIers set at a sensitivity of 5. The half-amp low-and high frequency bandpass fIlters were set at 0.3 and 30 Hz, respectively (24 dB/octave). A 60-Hz notch fIlter attenu ated electrical noise. Electrodes and transducers were also affixed during the fIrst night of baseline sleep as sessment to identify respiratory disturbances and peri odic limb movement disorder.
A second series of 2-night PSG evaluations was con ducted "on drug" after 7 to 29 weeks (median 11.9 weeks) of treatment (T2). At T2, the individualized doses ranged from 10 to 50 mg/day (36.7 ± 10.0), prescribed in once-a-day or alternating daily regimens. At T2, seven of nine patients had achieved remission, which occurred between the 3rd and 14th week (me dian 8.0 weeks) of treatment with FLU. Remission was defIned as an HDRS-D score less than or equal to 9 and an IDS-C score less than or equal to 14 for at least 2 con secutive weeks. The remaining two subjects responded signilicantly (T2 HDRS-D score = 11.0 ± 1.4). Table 2 shows the PSG p arameters at baseline (11) and after the acute treatment phase (T2).
Visual sleep-stage scoring was performed accord ing to standardized criteria (Rechtschaffen and Kales 1968) by personnel trained to better than 90% agree ment. Polysomnogram parameters that were computed at Tl and T2 included 1) total time in bed (TIB)-time in minutes from "lights out" to 'lights on"; 2) onset of total sleep period (TSp) l -the time of appearance of the half-minute epoch that initiates the frrst 10-minute period of recording that includes at least 8 minutes of any stage of non-REM sleep or the frrst epoch of REM sleep, whichever is sooner; 3) sleep latency -time from 'lights-out" to onset of TSP; 4) wake-up time (WUT) the frrst epoch of wake following the last 10-minute period of sleep that contains at least 8 minutes of any stage of sleep; 5) total sleep time (TST)-net minutes of sleep within TSP; 6) awake and movement time (AMT) -total minutes of AMI in the TSP and also in the frrst, second, and third one-thirds of the night; 7) stage 3 plus stage 4 sleep -total minutes of stage 3 com bined with stage 4; 8) sleep efficiency -percentage of TST in total TIB; 9) sleep efficiency minus non-REM stage 1 sleep -percentage of TST minus non-REM stage 1 in total TIB; and 10) REM latency-time from onset of TSP to the frrst half-minute epoch of REM sleep. REM density was scored on a 0 to 4-point scale for each min ute of REM sleep. Polysomnogram variables were aver aged across nights for each subject at each measure ment occasion (Tl and T2). Additional details relevant to scoring criteria are presented by Emslie et al. (1990) .
Weekly serum samples were obtained in the morn ing approximately 24 hours after the last medication dose, before ingestion of medication for that day. Blood was drawn for analysis at 8 AM (range 8 to 10 AM) fol lowing the second night of PSG recording at T2.
1 Total sleep period is often referred to as the period of persis tent sleep.
Fluoxetine and NFLU were isolated from serum by liquid-liquid extraction. They were then separated and quantified by reverse-phase, high-performance liquid chromatography (HPLC) with ultraviolet detection. Units reported are ng/ml. Within-run precision was de termined, yielding a coefficient of variation between 0.0% and 5.1% for FLU and 1.3% and 7.7% for NFLU. The between-run coefficient of variation was 4.1% to 6.8% for FLU and 6.2% to 8.8% for NFLU (Orsulak et al. 1988 ).
Statistical Analyses
The statistical analyses were divided into three parts.
First, to test for changes in PSG between T 1 and T 2, we conducted paired t-tests. Second, to measure the rela tionship between the FLU exposure and changes in PSG, correlations between these measures were con ducted. Third, we estimated sample sizes needed to replicate the fmding based on the regression results with power set at .80 and alpha at .05. All statistical analy ses were computed using a commercially available soft ware program (SAS Institute Inc. 1988) .
Contemporaneous FLU measures used in the anal yses included 1) current FLU dose; 2) FLU serum con centration; 3) NFLU serum concentration, and 4) total (FLU plus NFLU) serum concentration. Additional parameters designed as measures of cumulative effects of FLU treatment were cumulative oral dose at T2 and total area under the serum concentration curve (AUC) for FLU and NFLU (i.e., the serum concentration ana logs of cumulative oral dose). Cumulative FLU dose and AUC encompass the entire treatment period. The AUC was estimated by a straight-line fIt. A polygon was con- a Pearson product-moment correlation coeffIcient (n = 9).
structed using the weekly serum concentrations as its height and the days of treatment as its width. The area of the polygons estimated the Aues for both FLU and NFLU. Inasmuch as contemporaneous and cumulative measures were mathematically related, correlations among them are shown in Table 3 . Table 3 suggests that the four measures of contem poraneous FLU exposure and the four measures of cu mulative exposure have considerable overlap within each group of measures. The correlations between the contemporaneous and cumulative measures are lower, suggesting that the current and cumulative measures are less interdependent.
As a caution to the reader, the analyses reported in this paper are exploratory and designed to serve as a guide for future research. Both the t-test of PSG Tl to T 2 difference scores and the correlations between the exposure to FLU measures and PSG Tl to T2 differ ence scores are considered potentially confounded by the alleviation of depression. Although multivariate statistical analyses can be designed to test and sepa rate the influences of multiple effects, in this study with only a few subjects, it is either impossible to perform such analyses or the results may be misleading because they were conducted on a very small sample. In addi tion, no attempt was made to statistically correct for the number of tests being used and the probability reported should only be used as a guide to measures that would be useful in future research.
RESULTS
Overall Changes in the Polysomnogram
Results of the t-test of the differences between T 1 and T2 measures revealed an increase in stage 1 sleep, REM latency and REM density between Tl and T2 ( Table 2) .
Polysomnogram Changes in Relation to Medication Dose and Serum Concentrations
The correlations presented in Table 4 between FLU measures suggest the following relationships: 1) Ease Findings in the seven treatment remitters were equivalent to those of the group as a whole (n = 9), ex cept for a correlation between FLU AUe and AMT in the third one-third of the night (r = . 784) in the remit ters, which was not found for the complete sample.
Because these data were collected as a pilot study, we estimated the sample sizes needed to detect a rela tionship between FLU dose and serum concentrations and changes in PSG measures between Tl to T2. Based on these data, a wide range of sample sizes would be needed. For example, samples with 5 to 37 subjects would be sufficient to fmd signifIcant changes in total AMT in the frrst and third one-thirds of the night in re lation to FLU AUe. In contrast, to fmd a significant rela tionship between FLU A ue and minutes of stage 1 sleep would require a sample in the thousands.
DISCUSSION
In this sample of nine depressed patients who under went sleep studies before and during the course of treat ment with FLU, the drug appeared to alter both sleep continuity and sleep-stage architecture. Sleep changes observed between drug-free (pretreatment) and on medication (posttreatment) conditions were increases in REM latency, stage 1 sleep and REM density, and decreases in percent REM sleep. It appears that sleep shifted from deeper (non-REM stages 2, 3, and 4) to lighter stages with more wakefulness, although changes in the deeper sleep measures did not reach statistical signifIcance in this small sample. Cumulative treatment exposure particularly aff ected ease of falling asleep, conventional sleep efficiency, and wakefulness in the fust and last one-thirds of the night. The relationship of NFLU to wakefulness during sleep appeared to be greatest in the latter part of the night. The NFLU AUC correlated strongly with the decline in AMT in the last one-third of the night (reduction in "terminal" insomnia) and may be a marker of the an tidepressant effects of FLU. The meager amount of deep non-REM sleep and the great interindividual variabil ity evident at T 1 may explain the poor correlation be tween the decrements in deep non-REM sleep and FLU treatment (see Table 4 ). Overall, the cumulative meas ures appear to be somewhat more sensitive to sleep changes than contemporaneous measures.
The PSG changes that related to FLU and NFLU were in a direction opposite to changes that have been reported when there is a reduction in depressive symp toms. Increased REM latency and REM density and de creased percent REM, which were unrelated to FLU and NFLU measures, have been found with a reduction in depressive symptoms.
Other investigators have found that treatment with FLU affects the sleep of depressed patients (Kerkhofs et al. 1990; Keck et al. 1991) . However, Keck et al. (1991) reported baseline PSG data for only one patient in their sample (n = 7). Sleep continuity was disturbed, as ex emplifIed by increases in the number of arousals and sleep-stage shifts. Consistent with our data, the propor tion of stage 1 sleep seemed to increase, whereas deep non-REM sleep and sleep efficiency declined.
Suppression of REM sleep has been noted in pa tients treated with either FLU or amitriptyline (Kerkhofs et al. 1990) . Our fIndings are similar to those of Kerkhofs et al. (1990) , but provide an analysis of serum concentrations of FLU and NFLU as well.
Although we also found a lengthening of REM latency, an increase in REM density, and a reduction in overall REM percent, they did not correlate with the amount or duration of FLU treatment in this sample of patients. Such fIndings suggest that increased REM latency and decreased REM sleep, although occurring following exposure to many types of antidepressant drugs, are not uniquely related to specifIc characteris tics of drug dose and serum concentrations. However, because of the high interindividual variability of the T 2 REM latency in our subjects, a larger sample is needed to support this contention.
Single doses of FLU (20 to 80 mg) also aff ect the sleep of nondepressed, healthy adults (Nicholson and Pascoe 1988; Nicholson et al. 1989; von Bardeleben et al. 1989; Saletu et a1. 1991) . Sleep was found to be of poorer quality following a dose of FLU, with a rise in the number of arousals and in stage 1 sleep. Percent age of REM sleep was reduced and REM latency was lengthened, a fInding common to many antidepressant medications. However, results from single-dose studies have only a restricted application in the management of major depressive episodes during which antidepres sant agents are usually prescribed for weeks or months.
The pharmacodynamic properties of FLU and NFLU probably influence their effects on sleep. Follow ing an oral dose of FLU, peak serum concentrations are reached within 6 to 8 hours. Fluoxetine is extensively metabolized to equipotent NFLU. The long elimination half-life of FLU (2 to 3 days) and NFLU (5 to 9 days) assures a large accumulation of both substances. After multiple doses of FLU, serum concentrations and ra tios of FLU to NFLU are unpredictable (Lemberger et al. 1985; Stark et al. 1985; BenfIeld et al. 1986; Orsulak et al. 1988; Keck and McElroy 1992) . Accumulation of FLU and NFLU in the brain may contribute to both ther apeutic and toxic effects (Renshaw et al. 1992) .
Chronic alterations in sleep can cause excessive day time sleepiness. Patients who report this condition may metabolize FLU differently, resulting in an accumula tion of NFLU, which in turn, may exacerbate excessive daytime sleepiness. Keck and McElroy (1992) reported plasma FLU /NFLU ratios less than 1.0 in eight patients who reported excessive daytime sleepiness and ratios greater than 1.0 in those who did not report this phenomenon. However, it is also possible that the symptom of excessive daytime sleepiness follows upon the light and disrupted sleep secondary to FLU treat ment. Normal subjects have reported drowsiness on the day following a single dose of FLU. They also evi dence reduced coding ability and prolonged reaction times (Saletu and Grunberger 1985; Nicholson and Pas coe 1988) .
The cumulative effects of FLU may be important in elderly patients who are generally subject to more disturbed sleep and reduced daytime wakefulness than are younger adults (Czeisler et al. 1992; Bliwise 1993) . The elderly are sensitive to cumulative effects of drugs, particularly when multiple drugs are administered for concomitant systemic illnesses.
This preliminary study suggests that some of the cumulative effects of FLU and NFLU on sleep (i.e., sleep efficiency, sleep latency) may be different. In addition, the size of sleep changes may depend upon the dura tion and strength of exposure to one or the other sub stance. Certain PSG parameters, such as changes in REM latency or deep non-REM sleep, do not appear to correlate speciflcally with either FLU or NFLU parameters. This interpretation is consistent with the REM sleep differences reported after single doses and after chronic exposures of 30 days or longer, as noted above. A more defmitive study is needed to fully evalu ate the relative effects on the PSG of cumulative versus contemporaneous measures of FLU treatment.
Finally, several investigators have noted an increase in non-REM eye movements with FLU (Keck et al. 1990; Schenck et al. 1992) . Keck et al. (1990) have also shown that FLU-induced eye movements occur most often in stage 1 sleep. These eye movements can potentially compromise sleep-stage discrimination, perhaps result ing in the misclassiflcation of sleep stages. It is possible that the FLU-induced eye movements resulted in an increase in scorable stage 1 sleep, accompanied by a de crease in the identiflcation of stage 2 sleep. This poten tial sleep-stage misclassiflcation could have resulted in the decrease in stage 2 sleep observed upon treatment in this study. Upon reviewing the PSG records, FLU induced eye movements create the largest uncertainty in differentiating stage 1 from wakefulness and from REM sleep, which suggests that the decreased stage 2 sleep observed in this pilot study is unlikely to have resulted from sleep-stage misclassi&cation. However, to further clarify this issue, a systematic, quantitative study of the distribution of FLU-induced eye move ments across sleep is currently underway, including an assessment of interrater disagreement on sleep-stage classiflca tion.
The influence of FLU on sleep does not appear to hinder its efficacy in the acute treatment phase of ma jor depression. Lower doses (e.g., 10 mg/day) than those usually used in the acute treatment phase may produce or sustain a remission of symptoms without the excessive daytime sleepiness found with high se rum concentrations of NFLU. Our &ndings, if repli cated, would be consistent with the strategy of lower ing the dose of medication in subjects who have responded clinically to FLU, but who subsequently de velop an impairment in falling asleep or in maintain ing sleep (Cain 1992) .
